Roles of posttherapy 18 F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy

To assess the clinical roles of [ F]fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) performed 2-3 months after completion of concurrent chemoradiotherapy (CCRT), along with pretherapy characteristics, in patients with advanced squamous cell carcinoma of the uter...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2018-07, Vol.45 (7), p.1197
Main Authors: Liu, Feng-Yuan, Su, Tzu-Pei, Wang, Chun-Chieh, Chao, Angel, Chou, Hung-Hsueh, Chang, Yu-Chen, Yen, Tzu-Chen, Lai, Chyong-Huey
Format: Article
Language:English
Subjects:
Carcinoma, Squamous Cell - diagnostic imaging
Carcinoma, Squamous Cell - therapy
Chemoradiotherapy
Female
Fluorodeoxyglucose F18
Humans
Middle Aged
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Prospective Studies
Radiopharmaceuticals
Tomography, X-Ray Computed
Treatment Failure
Uterine Cervical Neoplasms - diagnostic imaging
Uterine Cervical Neoplasms - therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the clinical roles of [ F]fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) performed 2-3 months after completion of concurrent chemoradiotherapy (CCRT), along with pretherapy characteristics, in patients with advanced squamous cell carcinoma of the uterine cervix enrolled in a prospective randomized clinical trial. Posttherapy PET/CT in patients with advanced FIGO stage or positive pelvic or para-aortic lymph node (PALN) defined on pretherapy PET/CT was classified as positive, equivocal, or negative. Overall survival (OS) rates between patients with different PET/CT results are compared. Pretherapy characteristics are examined for association with posttherapy PET/CT results and for prognostic significance in patients with equivocal or negative PET/CT. PET/CT scans (n = 55) were positive, equivocal and negative in 9, 13 and 33 patients, respectively. All patients with positive scans were confirmed to have residual or metastatic disease and died despite salvage therapies. There is a significant OS difference between patients with positive and equivocal scans (P 
ISSN:1619-7089